ovarian fallopian primary peritoneal gynecology crg page 1 click here to prin t this page pdf click here to print this page pdf ovarian fallopian primary peritoneal platinum sensitive 1st recurrence gog0213 phase iii carboplatin paclitaxel bevacizumab then bevacizumab cytoreduction surgery pi berek gog stanford cancer center gynecology crg 10 january 2012 click here to print this page pdf please mark up a copy using black ink and fax changes to 725 9204 pending optional path open for enrollment link trial posting observational study enrollment on hold key gog0255 phase ii vaccine klh conjugate nsc 748933 opt 821 vs opt 821 in ovarian fallopian or peritoneal ca pi berek gog 2nd or 3rd remission platinum resistant previous taxol treatment previous doxil treatment gynova0017 phase iii ec145 pegylatetd liposomal doxorubicin pld vs pld in platinum resistant ovarian cancer pi berek pending gynopf0008 phase iii paclitaxel amg 386 or placebo in ovarian primary peritoneal or fallopian tube cancers pi teng amgen complete remission recurrent gynova0020 phase 3 farletuzumab morab 003 in combo w carboplatin & taxane in ovarian cancer in first relapse pi berek morphotek inc 1st priority 2nd priority gynova0021 phase i stereotactic body radiation for metastatic or recurrent platinum resistant ovarian cancer pi kim pending any previous treatment
